1 hr ago
Retatrutide Shows Potential to Deliver Twice Ozempic’s Weight Loss
Retatrutide is a new medicine being studied to help people lose weight.
It is not approved yet.
Its maker, Lilly, says it may ask United States regulators to review it in 2027.
Early results suggest it could help people lose about twice as much weight as Ozempic.
However, the medicine caused stomach and digestive problems for some people.
These included diarrhea, nausea, constipation and vomiting.
Some side effects happened more often with higher doses.
Scientists are also checking whether the weight people lose is mostly fat or healthy lean tissue.
Retatrutide is an unapproved weight-loss medication being developed by Lilly.
Lilly says it plans to submit retatrutide for United States regulatory review in 2027.
The drug’s reported weight-loss results could be about twice those associated with Ozempic.
TRIUMPH-2 reported gastrointestinal side effects including diarrhea, nausea, constipation and vomiting.
Researchers are still studying whether weight lost with retatrutide is fat or lean tissue.
- Who
- Lilly is developing retatrutide, while researchers are studying its effects.
- What
- An unapproved drug called retatrutide has shown potentially substantial weight loss in trials, alongside gastrointestinal side effects.
- Where
- The planned regulatory review would take place in the United States; the article does not specify where the trials occurred.
- When
- Lilly says it plans to submit retatrutide for United States regulatory review in 2027.
- Why
- The drug is being developed as a weight-loss treatment and is being studied for both its effectiveness and effects on body composition.
Potential Benefits
Safety Questions
Weight loss
Potential Benefits
Reported results suggest retatrutide could produce about twice as much weight loss as Ozempic.
Safety Questions
The article says researchers are still studying the treatment and its longer-term effects.
Treatment risks
Potential Benefits
The drug could offer another option for people seeking weight-loss treatment if it is eventually approved.
Safety Questions
TRIUMPH-2 reported gastrointestinal problems, with some occurring more often at higher doses; researchers are also examining how much lost weight is fat versus lean tissue.
Key facts
- Drug
- Retatrutide
- Developer
- Lilly
- Approval status
- Not yet approved as a weight-loss medication
- Planned regulatory submission
- United States review in 2027
- Reported comparison
- Potentially about twice the weight loss associated with Ozempic
- Trial referenced
- TRIUMPH-2
- Common reported reactions
- Diarrhea, nausea, constipation and vomiting
Sources
Related news
Doctor Warns High Ozempic Doses Require Careful Medical Oversight
Doctors Warn Against Treating Ozempic as a Weight-Loss Shortcut
Obesity Drugs Advance as Medicine Debates What Obesity Means
India’s Weight-Loss Drug Boom Fuels Fake Mounjaro Market
Purnia MP Pappu Yadav’s Weight Loss Fuels Ozempic Rumours
Microdosing GLP-1 Drugs Remains Uncertain for Weight Loss
Eli Lilly’s Mounjaro Approved to Reduce Cardiovascular Risks
